Placental abruption screening
Jump to navigation
Jump to search
|
Placental abruption Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Placental abruption screening On the Web |
|
American Roentgen Ray Society Images of Placental abruption screening |
|
Risk calculators and risk factors for Placental abruption screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Rana aljebzi, M.D.[2]
screeninig
- First trimester (pregnancy-associated placental protein-A [PAPP-A])
- second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth).[1]
- MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete.[2]
References
- ↑ Ananth CV, Wapner RJ, Ananth S, DʼAlton ME, Vintzileos AM (2017). "First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption". Obstet Gynecol. 129 (3): 465–472. doi:10.1097/AOG.0000000000001889. PMC 5367463. PMID 28178056.
- ↑ Leyendecker JR, DuBose M, Hosseinzadeh K, Stone R, Gianini J, Childs DD; et al. (2012). "MRI of pregnancy-related issues: abnormal placentation". AJR Am J Roentgenol. 198 (2): 311–20. doi:10.2214/AJR.11.7957. PMID 22268173.